NASDAQ:EBIO - Eleven Biotherapeutics Stock Price, Price Target & More

$2.35 -0.02 (-0.84 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$2.35
Today's Range$2.3201 - $2.60
52-Week Range$0.62 - $2.60
Volume7.68 million shs
Average Volume2.04 million shs
Market Capitalization$95.69 million
P/E Ratio-2.12
Dividend YieldN/A
Beta2.98

About Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive EBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for EBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EBIO
CUSIPN/A
Phone617-871-9911

Debt

Debt-to-Equity RatioN/A
Current Ratio3.17%
Quick Ratio3.17%

Price-To-Earnings

Trailing P/E Ratio-2.12
Forward P/E Ratio-4.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$430,000.00
Price / Sales235.55
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book4.12

Profitability

EPS (Most Recent Fiscal Year)($1.11)
Net Income$-29,020,000.00
Net MarginsN/A
Return on Equity-123.66%
Return on Assets-34.01%

Miscellaneous

Employees17
Outstanding Shares43,100,000

Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics (NASDAQ:EBIO) announced its quarterly earnings results on Friday, August, 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.28 million during the quarter. View Eleven Biotherapeutics' Earnings History.

What price target have analysts set for EBIO?

1 Wall Street analysts have issued twelve-month target prices for Eleven Biotherapeutics' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Eleven Biotherapeutics' stock price to reach $2.00 in the next year. View Analyst Ratings for Eleven Biotherapeutics.

Are investors shorting Eleven Biotherapeutics?

Eleven Biotherapeutics saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 1,340,692 shares, a decline of 45.3% from the March 15th total of 2,449,936 shares. Based on an average daily volume of 1,059,715 shares, the short-interest ratio is presently 1.3 days. Currently, 6.0% of the shares of the company are sold short.

Who are some of Eleven Biotherapeutics' key competitors?

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the folowing people:
  • Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
  • Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 59)
  • Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board

Has Eleven Biotherapeutics been receiving favorable news coverage?

News headlines about EBIO stock have trended somewhat positive on Thursday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a media sentiment score of 0.04 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 43.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Eleven Biotherapeutics' major shareholders?

Eleven Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (7.40%) and SABBY MANAGEMENT, LLC (7.40%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, Boxer Capital, Llc, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.

How do I buy shares of Eleven Biotherapeutics?

Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eleven Biotherapeutics' stock price today?

One share of EBIO stock can currently be purchased for approximately $2.35.

How big of a company is Eleven Biotherapeutics?

Eleven Biotherapeutics has a market capitalization of $95.69 million and generates $430,000.00 in revenue each year. The biopharmaceutical company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Eleven Biotherapeutics employs 17 workers across the globe.

How can I contact Eleven Biotherapeutics?

Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]


MarketBeat Community Rating for Eleven Biotherapeutics (EBIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eleven Biotherapeutics (NASDAQ:EBIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Eleven Biotherapeutics in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible downside of 14.89%. The high price target for EBIO is $2.00 and the low price target for EBIO is $2.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00N/AN/A
Price Target Upside: 14.89% downside90.48% upsideN/AN/A

Eleven Biotherapeutics (NASDAQ:EBIO) Consensus Price Target History

Price Target History for Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics (NASDAQ:EBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018HC WainwrightSet Price TargetBuy$2.00LowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Eleven Biotherapeutics (NASDAQ:EBIO) Earnings History and Estimates Chart

Earnings by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics (NASDAQ:EBIO) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.52 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS

Eleven Biotherapeutics (NASDAQ EBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/20/2017Q3 2017($0.37)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.30)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.25)$0.43 millionViewListenView Earnings Details
3/24/2017Q4 2016($0.12)($0.20)$0.83 millionViewN/AView Earnings Details
11/14/2016Q3($0.17)$0.91$28.70 millionViewListenView Earnings Details
8/12/2016Q2($0.33)$0.28 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.39)$0.23 millionViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)$0.57 millionViewN/AView Earnings Details
11/4/2015Q315($0.44)($0.50)$0.10 million$0.07 millionViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)$0.20 million$0.11 millionViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)$0.20 million$0.24 millionViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$0.80 million$0.38 millionViewListenView Earnings Details
11/13/2014Q314($0.45)($0.66)$0.70 million$0.54 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.47)($0.51)$0.10 million$0.76 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.36)($0.80)$0.57 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eleven Biotherapeutics (NASDAQ:EBIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Eleven Biotherapeutics (NASDAQ EBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 15.43%
Insider Trading History for Eleven Biotherapeutics (NASDAQ:EBIO)
Institutional Ownership by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics (NASDAQ EBIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/28/2016Abbie CelnikerDirectorSell10,031$3.00$30,093.00409,915View SEC Filing  
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.007,329View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32419,946View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.7632,753View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.278,499View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75429,975View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.2034,648View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eleven Biotherapeutics (NASDAQ EBIO) News Headlines

Source:
DateHeadline
Rounds Report: Eleven Biotherapeutics Traded Further North While The Higher FDA Budget Foretells More ApprovalsRounds Report: Eleven Biotherapeutics Traded Further North While The Higher FDA Budget Foretells More Approvals
seekingalpha.com - April 25 at 9:30 AM
Rounds Report: Eleven Train Took Off While Improved FDA Policy Favors Infectious Disease InnovatorsRounds Report: Eleven Train Took Off While Improved FDA Policy Favors Infectious Disease Innovators
seekingalpha.com - April 24 at 9:24 AM
Eleven Biotherapeutics: An Assessment Of A Potential Big WinnerEleven Biotherapeutics: An Assessment Of A Potential Big Winner
seekingalpha.com - April 23 at 4:28 PM
Todays Research Reports on Trending Tickers: Eleven Biotherapeutics and CVS HealthToday's Research Reports on Trending Tickers: Eleven Biotherapeutics and CVS Health
finance.yahoo.com - April 23 at 9:08 AM
Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?
finance.yahoo.com - April 22 at 9:13 AM
Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% HigherEleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher
finance.yahoo.com - April 20 at 9:36 AM
Eleven Biotherapeutics (EBIO) PT Set at $2.00 by HC WainwrightEleven Biotherapeutics (EBIO) PT Set at $2.00 by HC Wainwright
www.americanbankingnews.com - April 18 at 9:53 AM
Eleven Biotherapeutics (EBIO) Expected to Post Earnings of -$0.13 Per ShareEleven Biotherapeutics (EBIO) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 16 at 9:25 AM
Short Interest in Eleven Biotherapeutics (EBIO) Decreases By 45.3%Short Interest in Eleven Biotherapeutics (EBIO) Decreases By 45.3%
www.americanbankingnews.com - April 14 at 2:29 AM
HC Wainwright Reiterates Buy Rating for Eleven Biotherapeutics (EBIO)HC Wainwright Reiterates Buy Rating for Eleven Biotherapeutics (EBIO)
www.americanbankingnews.com - April 12 at 10:45 AM
Eleven Biotherapeutics (EBIO) Says New Preclinical Data Highlighting its DeBouganin Program to be Presented at AACREleven Biotherapeutics (EBIO) Says New Preclinical Data Highlighting its DeBouganin Program to be Presented at AACR
www.streetinsider.com - April 12 at 10:17 AM
3 Things In Biotech, April 6: Bristols Kidney Coup, Astras Advanced Antibody, Elevens Mysterious Presentation3 Things In Biotech, April 6: Bristol's Kidney Coup, Astra's Advanced Antibody, Eleven's Mysterious Presentation
seekingalpha.com - April 7 at 9:57 AM
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development ...Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development ...
www.businesswire.com - April 4 at 5:00 PM
BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22
www.reuters.com - April 4 at 5:00 PM
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development ProgressEleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
finance.yahoo.com - April 4 at 5:00 PM
Eleven Bio up 22% on bullish expectations for late-stage Vicinium dataEleven Bio up 22% on bullish expectations for late-stage Vicinium data
seekingalpha.com - April 3 at 4:33 PM
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American ...Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American ...
www.businesswire.com - April 3 at 9:44 AM
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual MeetingPreliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
finance.yahoo.com - April 3 at 9:44 AM
 Analysts Anticipate Eleven Biotherapeutics (EBIO) to Post -$0.17 Earnings Per Share Analysts Anticipate Eleven Biotherapeutics (EBIO) to Post -$0.17 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:34 AM
Eleven Biotherapeutics (EBIO) Upgraded at ValuEngineEleven Biotherapeutics (EBIO) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Your Daily Pharma Scoop: Achaogens Plazomicin, Eiger Provides Update On Llonafarnib, Eleven Biotherapeutics Obtains FundingYour Daily Pharma Scoop: Achaogen's Plazomicin, Eiger Provides Update On Llonafarnib, Eleven Biotherapeutics Obtains Funding
seekingalpha.com - March 24 at 4:24 PM
Eleven Biotherapeutics (EBIO) Prices $10M Offering of Common Stock, Warrants - StreetInsider.comEleven Biotherapeutics (EBIO) Prices $10M Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - March 21 at 10:33 AM
Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-MarketEleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market
finance.yahoo.com - March 21 at 10:33 AM
Benzingas Top Upgrades, Downgrades For March 20, 2018 - BenzingaBenzinga's Top Upgrades, Downgrades For March 20, 2018 - Benzinga
www.benzinga.com - March 20 at 4:23 PM
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be Major Catalyst - BenzingaFor Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst' - Benzinga
www.benzinga.com - March 20 at 4:23 PM
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be Major CatalystFor Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'
finance.yahoo.com - March 20 at 4:23 PM
Eleven Biotherapeutics (EBIO) Coverage Initiated by Analysts at HC WainwrightEleven Biotherapeutics (EBIO) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - March 20 at 11:56 AM
Eleven Biotherapeutics (EBIO) Reports Completed Enrollment in VISTA Phase 3 Registration Trial of Vicinium - StreetInsider.comEleven Biotherapeutics (EBIO) Reports Completed Enrollment in VISTA Phase 3 Registration Trial of Vicinium - StreetInsider.com
www.streetinsider.com - March 12 at 11:05 AM
Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care ConferenceEleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 9:38 AM
Eleven Biotherapeutics (EBIO) Presents At BIO CEO & Investor Conference - SlideshowEleven Biotherapeutics (EBIO) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 4:24 PM
Eleven Biotherapeutics Inc (EBIO) Short Interest UpdateEleven Biotherapeutics Inc (EBIO) Short Interest Update
www.americanbankingnews.com - February 9 at 5:01 PM
Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor ConferenceEleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 8:53 AM
Eleven Biotherapeutics (EBIO) Names Richard Fitzgerald as CFOEleven Biotherapeutics (EBIO) Names Richard Fitzgerald as CFO
www.streetinsider.com - January 25 at 9:11 AM
Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial OfficerEleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer
finance.yahoo.com - January 24 at 4:41 PM
Eleven Biotherapeutics (EBIO) & Lipocine (LPCN) Head-To-Head SurveyEleven Biotherapeutics (EBIO) & Lipocine (LPCN) Head-To-Head Survey
www.americanbankingnews.com - January 22 at 9:28 AM
Eleven Biotherapeutics to Present at Biotech Showcase 2018Eleven Biotherapeutics to Present at Biotech Showcase 2018
finance.yahoo.com - January 2 at 6:33 PM
Eleven Biotherapeutics (EBIO) vs. KemPharm (KMPH) Head-To-Head AnalysisEleven Biotherapeutics (EBIO) vs. KemPharm (KMPH) Head-To-Head Analysis
www.americanbankingnews.com - December 21 at 11:54 PM
Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and ... - Business Wire (press release)Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and ... - Business Wire (press release)
www.businesswire.com - December 13 at 9:53 AM
Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics MeetingEleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting
finance.yahoo.com - December 13 at 9:53 AM
Eleven Biotherapeutics to Present at the LD Micro Main Event 2017Eleven Biotherapeutics to Present at the LD Micro Main Event 2017
finance.yahoo.com - November 30 at 5:10 PM
Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results - Business Wire (press release)Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - November 21 at 12:03 AM
Eleven Biotherapeutics Reports Third Quarter 2017 Financial ResultsEleven Biotherapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 20 at 6:58 PM
Eleven Biotherapeutics, Inc.: Sudden move in price, will it continue?Eleven Biotherapeutics, Inc.: Sudden move in price, will it continue?
finance.yahoo.com - November 20 at 6:58 PM
Eleven Biotherapeutics (EBIO) Presents At Stifel 2017 Healthcare Conference - SlideshowEleven Biotherapeutics (EBIO) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 16 at 6:42 PM
Edited Transcript of EBIO earnings conference call or presentation 14-Nov-17 9:30pm GMTEdited Transcript of EBIO earnings conference call or presentation 14-Nov-17 9:30pm GMT
finance.yahoo.com - November 16 at 1:41 PM
Eleven Biotherapeutics (EBIO) CEO Stephen Hurly on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaEleven Biotherapeutics' (EBIO) CEO Stephen Hurly on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 14 at 11:32 PM
Eleven Biotherapeutics, Inc. to Host Earnings CallEleven Biotherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 14 at 6:32 PM
Eleven Biotherapeutics (EBIO) versus Ra Pharmctl (RARX) Head-To-Head AnalysisEleven Biotherapeutics (EBIO) versus Ra Pharmctl (RARX) Head-To-Head Analysis
www.americanbankingnews.com - November 10 at 11:28 PM
Eleven Biotherapeutics to Present at Stifel 2017 Healthcare ConferenceEleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 10 at 11:47 AM
Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
finance.yahoo.com - November 10 at 11:47 AM

SEC Filings

Eleven Biotherapeutics (NASDAQ:EBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eleven Biotherapeutics (NASDAQ:EBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eleven Biotherapeutics (NASDAQ EBIO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.